Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
作者: Aly-Khan A. LalaniRana R. McKayXun LinRonit SimantovMarina D. KaymakcalanToni K. Choueiri
作者单位: 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, CA
3Pfizer Oncology, Pfizer Inc, New York, NY
4Department of Pharmacy and Clinical Support, Dana-Farber Cancer Institute, Boston, MA
刊名: Clinical Genitourinary Cancer, 2017, Vol.15 (6), pp.724-732
来源数据库: Elsevier Journal
DOI: 10.1016/j.clgc.2017.05.019
关键词: MRCCPPITargeted therapyTKIVEGF
英文摘要: Abstract(#br)Introduction(#br)Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion and can affect the optimal absorption of concomitant oral medications, such as vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs). The purpose of this study was to investigate the effect of PPI use on survival in metastatic renal cell carcinoma (mRCC) patients treated in the targeted therapy era.(#br)Materials and Methods(#br)We conducted a pooled analysis of mRCC patients treated in phase II and III clinical trials. Statistical analyses were performed using Cox regression adjusted for several risk factors and the Kaplan–Meier method.(#br)Results(#br)We identified 2188 patients treated with sunitinib (n = 952), axitinib (n = 626) or sorafenib (n = 610), of...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:1.429 (2012)

×